Cullinan Therapeutics, Inc.
CGEM Nasdaq
SEC CIK 1789972
Follow Cullinan Therapeutics
Weekly email: filings, results
Net income
−$49.4M
+2.4% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$43.1M
−16.8% vs same quarter last year
Operating income
−$52.6M
+5.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$219.9M |
| FY24 | - | −$167.6M |
| FY23 | - | −$155.1M |
| FY22 | $0 | $111.2M |
| FY21 | $18.9M | −$65.6M |
| FY20 | $0 | −$51.8M |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$175.8M |
| FY24 | −$145.3M |
| FY23 | −$134.5M |
| FY22 | −$127.8M |
| FY21 | −$43.4M |
| FY20 | −$29.8M |
| FY19 | - |